INB Biotechnologies

INB Biotechnologies is a South Korean clinical-stage biotechnology company dedicated to developing innovative vaccines using its proprietary Virus-Like Particle (VLP) platform. The company focuses on high-impact infectious diseases, with a pipeline that includes candidates for COVID-19, Norovirus, and Respiratory Syncytial Virus (RSV). Their lead program, IN-B001, is a VLP-based COVID-19 vaccine designed to elicit robust immune responses while maintaining a high safety profile. By leveraging VLP technology, which mimics the external structure of viruses without the infectious genetic material, INB Biotechnologies aims to create vaccines with superior stability and immunogenicity. The company maintains strategic collaborations with the International Vaccine Institute (IVI) to advance its clinical trials and support global health initiatives. Headquartered in South Korea, INB Biotechnologies is positioned as a key player in the next generation of vaccine development.